Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.21B P/E - EPS this Y 11.10% Ern Qtrly Grth -
Income -17.56M Forward P/E 29.77 EPS next Y 150.00% 50D Avg Chg 5.00%
Sales 197.71M PEG - EPS past 5Y - 200D Avg Chg -16.00%
Dividend N/A Price/Book 2.86 EPS next 5Y - 52W High Chg -44.00%
Recommedations 2.20 Quick Ratio 6.15 Shares Outstanding 131.51M 52W Low Chg 38.00%
Insider Own 8.62% ROA -3.01% Shares Float 113.36M Beta 1.31
Inst Own 58.67% ROE -4.32% Shares Shorted/Prior 4.08M/4.58M Price 8.93
Gross Margin 54.97% Profit Margin -8.88% Avg. Volume 998,269 Target Price 8.70
Oper. Margin -18.29% Earnings Date Aug 6 Volume 361,666 Change 0.34%
About Cytek Biosciences, Inc.

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

Cytek Biosciences, Inc. News
11/20/24 Cytek Biosciences to participate in the Piper Sandler 36th Annual Healthcare Conference
11/19/24 Cytek® Biosciences Named “Overall BioTech Company of the Year” in 2024 BioTech Breakthrough Awards Program
11/07/24 Cytek® Biosciences Becomes First Company to Add Ability to Detect Subcellular Particles to Its Cell Sorter
11/07/24 Cytek Biosciences Third Quarter 2024 Earnings: Beats Expectations
11/06/24 Cytek Biosciences Inc (CTKB) Q3 2024 Earnings Call Highlights: Revenue Growth and Positive Net ...
11/05/24 Cytek Biosciences, Inc. (CTKB) Q3 Earnings and Revenues Beat Estimates
11/05/24 Cytek Biosciences Reports Third Quarter 2024 Financial Results
11/01/24 November 2024's Top US Penny Stocks With Growth Potential
10/30/24 Cytek Biosciences to Participate in Upcoming Investor Conferences
10/29/24 Cytek Biosciences to Report Third Quarter 2024 Financial Results on November 5, 2024
09/18/24 Cytek® Biosciences Brings Full Spectrum Profiling™ (FSP™) Technology to the Forefront at Major Clinical Conferences in the U.S. and Europe
09/18/24 Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Intrinsic Value Is Potentially 99% Above Its Share Price
09/12/24 Cytek Announces Resignation of Chief Operating Officer Chris Williams
04:00 PM Cytek® Biosciences Achieves ISO 13485 Certification at San Diego Reagent Manufacturing Facility
08/08/24 Cytek Biosciences Second Quarter 2024 Earnings: Misses Expectations
08/06/24 Cytek Biosciences, Inc. (CTKB) Reports Q2 Loss, Lags Revenue Estimates
08/06/24 Cytek Biosciences Reports Second Quarter 2024 Financial Results
07/30/24 Cytek® Biosciences Automates Panel Design with New Intelligent Algorithm
07/30/24 Cytek Biosciences to Report Second Quarter 2024 Financial Results on August 6, 2024
07/22/24 Cytek Biosciences, Inc. (NASDAQ:CTKB) is a favorite amongst institutional investors who own 51%
CTKB Chatroom

User Image topstockalerts Posted - 2 weeks ago

Top Gainers PT2 $ELWS $GEO $DPST $CTKB $TMCI Details: https://topstockalerts.com/market-gainers-and-losers/

User Image VrtcIl Posted - 2 weeks ago

How much more potential do you see on $CTKB? 8? 12? 16? Look for key indicators such as trend strength, support and resistance levels, and potential breakout or reversal patterns. Price: 7.44 Float: 116.2M Short Float: 3.8 % 💰 Dollar Volume: 5.6K ℹ️ USA | Medical Devices

User Image topstockalerts Posted - 2 weeks ago

Top Gainers PT2 $ELWS $GEO $DPST $CTKB $TMCI Details: https://topstockalerts.com/market-gainers-and-losers/

User Image DipBuyInvester Posted - 2 weeks ago

$CTKB LGHL moving up!!

User Image nobodyspecial07 Posted - 2 weeks ago

$ELWS On its way back to 6! RSI in the 60's, MACD is bullish, and shorts need to pay 148% to hold a losing position. Except the 1 short who wised up and covered already. I see $SGBX $GEO and $CTKB are also moving up.

User Image UnicornPicks Posted - 2 weeks ago

$GELS $CTKB watching these

User Image KUMU Posted - 2 weeks ago

$CTKB swing trade

User Image DonCorleone77 Posted - 2 weeks ago

$CTKB Cytek Biosciences reports Q3 EPS 1c, consensus (2c) Reports Q3 revenue $51.5M, consensus $50.7M."We delivered solid year-over-year revenue growth in the third quarter of 2024 despite persistent industry headwinds, demonstrating how we are leading with the strength of our portfolio, loyal customer base and reputation in serving growing markets that need better technology for cell analysis," said Dr. Wenbin Jiang, CEO of Cytek Biosciences. "As we look ahead, we remain focused on strong execution of our growth pillars and building on the positive momentum we are seeing with the demand for our products. With the combination of our industry-leading end-to-end technology portfolio, global diversification and clear long-term growth drivers, we believe we are fundamentally well positioned to deliver sustainable growth and profitability."

User Image WeeklyTrader Posted - 10/23/24

Who's ready to capitalize on $CTKB? RSI: 46.03% 50-day MA: $5.29 200-day MA: $6.36

User Image WeeklyTrader Posted - 1 month ago

The market is heating up! Grab a CALL on $CTKB at strike None! RSI: 52.62% 50-day MA: $5.31 200-day MA: $6.47

User Image PenkeTrading Posted - 2 months ago

I found you a Bearish Engulfing Candle Pattern on the daily chart of Cytek Biosciences Inc. $CTKB #BearishEngulfingCandle #NASDAQ

User Image Stock_Titan Posted - 2 months ago

$CTKB Cytek® Biosciences Brings Full Spectrum Profiling™ (FSP™) Technology to the Forefront at Major Clinical Conferences in the U.S. and Europe https://www.stocktitan.net/news/CTKB/cytek-r-biosciences-brings-full-spectrum-profiling-fsp-technology-to-x0xtd8szh6ue.html

User Image DonCorleone77 Posted - 2 months ago

$CTKB Cytek Biosciences announces resignation of Chief Operating Officer Cytek Biosciences announced that its Chief Operating Officer, Chris Williams, will resign his position effective September 27, to accept a CEO position at another company. "Cytek has chosen not to replace the COO position, opting instead to restructure the organization to create a flatter, more efficient management structure," the company stated. Williams will remain with Cytek until September 27 to ensure a smooth transition and assist with the restructuring process, the company added.

User Image Stock_Titan Posted - 3 months ago

$CTKB Cytek Biosciences Reports Second Quarter 2024 Financial Results https://www.stocktitan.net/news/CTKB/cytek-biosciences-reports-second-quarter-2024-financial-c0cjzx65ehuf.html

User Image Stock_Titan Posted - 07/30/24

$CTKB Cytek Biosciences to Report Second Quarter 2024 Financial Results on August 6, 2024 https://www.stocktitan.net/news/CTKB/cytek-biosciences-to-report-second-quarter-2024-financial-results-on-fn69t42mgkxn.html

User Image NVDAMillionaire Posted - 07/29/24

$CTKB Cytek Biosciences, Inc. (NASDAQ:CTKB) – Advancing Next-Generation Cell Analysis with Robust Growth and Profitability http://beyondspx.com/2024/07/29/cytek-biosciences-inc-nasdaqctkb-advancing-next-generation-cell-analysis-with-robust-growth-and-profitability/

User Image TickerDD_com Posted - 4 months ago

From 6/21/2024, looking back across 21 Month-Ends for CTKB, Percentage Change of Average Monthly Price had More Negatives (55%) while Percentage Change of Average Monthly Volume had All Positives (100%) $CTKB #CTKB #CTKBStock #TickerDD #CTKBPrice https://www.youtube.com/watch?v=NTGrh9x8KEM

User Image DoolieBirdTheCollector Posted - 5 months ago

@PutridCoast @CryptoPlaya keep an eye on $CTKB

User Image DoolieBirdTheCollector Posted - 5 months ago

$CTKB watching

User Image Stock_Titan Posted - 5 months ago

$CTKB Cytek Biosciences Announces $50 Million Stock Repurchase Program https://www.stocktitan.net/news/CTKB/cytek-biosciences-announces-50-million-stock-repurchase-d6pd3t027s48.html

User Image DonCorleone77 Posted - 05/29/24

$CTKB Cytek's laser receives approval for clinical diagnostic use in China Cytek Biosciences announced that its 1-laser and 2-laser 6-color TBNK reagent cocktails have received China National Medical Products Administration, or NMPA approval for clinical diagnostic use on the Cytek Northern Lights-Clinical, or NL-CLC, cell analysis systems in hospitals, laboratories and clinics across China. This is the first clinical 1-laser based 6-color TBNK assay supported by Full Spectrum Profiling capability. Clinical TBNK analysis is routinely used to assess and monitor immune system status for various medical conditions, with TBNK reagents enabling the identification and quantification of key lymphocyte subsets. These reagents help in diagnosing and monitoring various immune-related conditions, including immunodeficiencies, autoimmune diseases, infectious diseases and cancers. By providing insight into the immune system's composition, function, and therapeutic response, TBNK reagents support targeted treatment decisions and ongoing patient management.

User Image Stock_Titan Posted - 05/28/24

$CTKB 1-Laser and 2-Laser 6-Color TBNK Reagents from Cytek® Biosciences Approved for Clinical Use in China https://www.stocktitan.net/news/CTKB/1-laser-and-2-laser-6-color-tbnk-reagents-from-cytek-r-biosciences-41towyam864b.html

User Image Stock_Titan Posted - 6 months ago

$CTKB Cytek® Biosciences Adds Ability to Detect Subcellular Particles to Its Industry-Leading Cell Analysis Systems https://www.stocktitan.net/news/CTKB/cytek-r-biosciences-adds-ability-to-detect-subcellular-particles-to-5bl896017u3z.html

User Image Stock_Titan Posted - 6 months ago

$CTKB Cytek Biosciences Reports First Quarter 2024 Financial Results https://www.stocktitan.net/news/CTKB/cytek-biosciences-reports-first-quarter-2024-financial-3o39frzsrr2r.html

User Image StockInvest_us Posted - 6 months ago

Signal alert: $CTKB - PivotPoint bottom https://stockinvest.us/l/x2F21fjlE7

User Image Stock_Titan Posted - 04/30/24

$CTKB Cytek® Biosciences to Spotlight Cell Analysis Solutions at Upcoming Conferences in the United States and Europe https://www.stocktitan.net/news/CTKB/cytek-r-biosciences-to-spotlight-cell-analysis-solutions-at-upcoming-i7o40xcrbv25.html

User Image Stock_Titan Posted - 04/29/24

$CTKB Cytek Biosciences to Report First Quarter 2024 Financial Results on May 8, 2024 https://www.stocktitan.net/news/CTKB/cytek-biosciences-to-report-first-quarter-2024-financial-results-on-kfob7em544te.html

User Image insiderbuyingselling Posted - 04/23/24

$CTKB new insider selling: 20000 shares. http://insiderbuyingselling.com/?t=CTKB

User Image insiderbuyingselling Posted - 7 months ago

$CTKB new insider selling: 1900 shares. http://insiderbuyingselling.com/?t=CTKB

User Image Stock_Titan Posted - 8 months ago

$CTKB Cytek® Biosciences Names William McCombe Chief Financial Officer https://www.stocktitan.net/news/CTKB/cytek-r-biosciences-names-william-mc-combe-chief-financial-baiaewypq5cf.html

Analyst Ratings
Piper Sandler Overweight Aug 13, 24
Piper Sandler Overweight May 13, 24
Piper Sandler Overweight Mar 6, 24
Goldman Sachs Buy Feb 29, 24
Stephens & Co. Overweight Dec 14, 23
Morgan Stanley Equal-Weight Nov 9, 23
Morgan Stanley Equal-Weight Oct 24, 23
Piper Sandler Overweight Oct 16, 23
Raymond James Market Perform Jul 19, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Jeanmonod Patrik Chief Financial Offi.. Chief Financial Officer Dec 26 Sell 9.50 3,000 28,500 93,400 12/27/23
Yan Ming Chief Technology Off.. Chief Technology Officer Dec 19 Sell 9.43 20,000 188,600 6,042,103 12/21/23
Jeanmonod Patrik Chief Financial Offi.. Chief Financial Officer Nov 24 Sell 6.94 3,000 20,820 96,400 11/27/23
Yan Ming Chief Technology Off.. Chief Technology Officer Nov 18 Sell 6.03 20,000 120,600 7,762,103 11/21/23
Jiang Wenbin President and CEO President and CEO Nov 07 Sell 4.34 20,000 86,800 5,275,796 11/08/23
Jeanmonod Patrik Chief Financial Offi.. Chief Financial Officer Oct 24 Sell 4.68 3,000 14,040 96,084 10/25/23
Yan Ming Chief Technology Off.. Chief Technology Officer Oct 19 Sell 4.80 20,000 96,000 7,775,962 10/23/23
Jiang Wenbin President and CEO President and CEO Oct 09 Sell 5.33 20,000 106,600 5,295,796 10/11/23
Jeanmonod Patrik Chief Financial Offi.. Chief Financial Officer Sep 25 Sell 6.38 3,000 19,140 99,084 09/26/23
Yan Ming Chief Technology Off.. Chief Technology Officer Sep 19 Sell 6.49 20,000 129,800 7,795,962 09/20/23
Jiang Wenbin President and CEO President and CEO Sep 07 Sell 6.83 20,000 136,600 7,605,796 09/08/23
Jeanmonod Patrik Chief Financial Offi.. Chief Financial Officer Aug 24 Sell 7.69 3,000 23,070 102,084 08/28/23
Yan Ming Chief Technology Off.. Chief Technology Officer Aug 18 Sell 8.07 20,000 161,400 7,815,962 08/21/23
Jiang Wenbin President and CEO President and CEO Aug 07 Sell 9.04 20,000 180,800 7,613,467 08/08/23
Jeanmonod Patrik Chief Financial Offi.. Chief Financial Officer Jul 24 Sell 9.17 3,000 27,510 101,768 07/25/23
Yan Ming Chief Technology Off.. Chief Technology Officer Jul 19 Sell 8.76 20,000 175,200 7,830,258 07/20/23
Jiang Wenbin President and CEO President and CEO Jul 07 Sell 8.48 20,000 169,600 7,633,467 07/07/23
Jeanmonod Patrik Chief Financial Offi.. Chief Financial Officer Jun 26 Sell 7.96 3,000 23,880 104,768 06/27/23
Yan Ming Chief Technology Off.. Chief Technology Officer Jun 20 Sell 8.18 20,000 163,600 7,850,258 06/21/23
Jiang Wenbin President and CEO President and CEO Jun 07 Sell 8.23 20,000 164,600 7,653,467 06/07/23
Jeanmonod Patrik Chief Financial Offi.. Chief Financial Officer May 24 Sell 7.76 3,000 23,280 107,768 05/25/23
Yan Ming Chief Technology Off.. Chief Technology Officer May 18 Sell 7.19 20,000 143,800 7,870,258 05/19/23
Jiang Wenbin President and CEO President and CEO May 08 Sell 11.55 20,000 231,000 7,664,439 05/10/23
Jeanmonod Patrik Chief Financial Offi.. Chief Financial Officer Apr 24 Sell 10.24 3,000 30,720 108,201 04/25/23
Yan Ming Chief Technology Off.. Chief Technology Officer Apr 19 Sell 9.71 20,000 194,200 7,886,053 04/20/23
Jiang Wenbin President and CEO President and CEO Apr 10 Sell 8.88 20,000 177,600 7,684,439 04/11/23
Jeanmonod Patrik Chief Financial Offi.. Chief Financial Officer Mar 24 Sell 8.33 3,000 24,990 111,201 03/24/23
Yan Ming Chief Technology Off.. Chief Technology Officer Mar 20 Sell 9.29 20,000 185,800 7,906,053 03/21/23
Jiang Wenbin President and CEO President and CEO Mar 03 Sell 10.13 20,000 202,600 7,704,439 03/07/23
Yan Ming Chief Technology Off.. Chief Technology Officer Feb 21 Sell 10.94 20,000 218,800 7,926,053 02/23/23
Jeanmonod Patrik Chief Financial Offi.. Chief Financial Officer Sep 08 Option 0.40 40,000 16,000 116,132 02/23/23
Jiang Wenbin President and CEO President and CEO Feb 07 Sell 13.19 20,000 263,800 7,720,314 02/08/23
Yan Ming Chief Technology Off.. Chief Technology Officer Feb 03 Sell 13.51 1,092 14,753 7,945,741 02/07/23
Jeanmonod Patrik Chief Financial Offi.. Chief Financial Officer Jan 24 Sell 11.05 3,500 38,675 76,132 01/25/23
Yan Ming Chief Technology Off.. Chief Technology Officer Jan 19 Sell 11.03 20,000 220,600 7,946,833 01/20/23
Jiang Wenbin President and CEO President and CEO Jan 09 Sell 10.66 20,000 213,200 7,740,314 01/10/23
Yan Ming Chief Technology Off.. Chief Technology Officer Dec 19 Sell 10.38 20,000 207,600 7,966,833 12/20/22
Jiang Wenbin President and CEO President and CEO Dec 07 Sell 11.86 20,000 237,200 7,760,314 12/09/22
Ball Jack Director Director Nov 29 Option 0.66 23,999 15,839 26,999 11/30/22
Jeanmonod Patrik Chief Financial Offi.. Chief Financial Officer Nov 25 Sell 14.30 3,500 50,050 83,132 11/28/22
Ball Jack Director Director Nov 14 Option 0.4 16,000 6,400 19,000 11/16/22
Ball Jack Director Director Nov 14 Sell 14.69 16,000 235,040 3,000 11/16/22
Jiang Wenbin President and CEO President and CEO Nov 07 Sell 14.76 20,000 295,200 7,785,820 11/08/22
Yan Ming Chief Technology Off.. Chief Technology Officer Oct 19 Sell 14.42 20,000 288,400 8,005,624 10/20/22
Jeanmonod Patrik Chief Financial Offi.. Chief Financial Officer Sep 26 Sell 12.63 3,500 44,205 89,063 09/28/22
Jiang Wenbin President and CEO President and CEO Sep 07 Sell 12.89 20,000 257,800 7,825,820 09/09/22
Jeanmonod Patrik Chief Financial Offi.. Chief Financial Officer Aug 24 Sell 13.45 3,500 47,075 92,563 08/25/22
Yan Ming Chief Technology Off.. Chief Technology Officer Aug 18 Sell 13.62 20,000 272,400 8,045,624 08/19/22
Jiang Wenbin President and CEO President and CEO Aug 08 Sell 15.09 20,000 301,800 7,841,541 08/10/22
Jeanmonod Patrik Chief Financial Offi.. Chief Financial Officer Aug 01 Sell 12.80 3,500 44,800 94,994 08/03/22